Literature DB >> 20507651

Comparison of settings used for high-frequency chest-wall compression in cystic fibrosis.

Robert R Kempainen1, Carlos Milla, Jordan Dunitz, Kay Savik, Ann Hazelwood, Cynthia Williams, Bruce K Rubin, Joanne L Billings.   

Abstract

BACKGROUND: Cystic fibrosis (CF) patients commonly use a high-frequency chest-wall compression (HFCWC) device for airway clearance that generates oscillatory flow with a sine-wave configuration. Typical HFCWC settings combine a lower Vest inflation pressure setting (eg, 5 on the Vest's arbitrary 1-10 scale for the setting that controls the background pressure of the inflatable vest) with mid-range frequency (14-16 Hz) (lower-pressure/mid-frequency HFCWC).
OBJECTIVE: To determine whether HFCWC with higher pressure settings (6-10 on the Hill-Rom Vest's arbitrary 1-10 scale) combined with variable mid-frequencies (8, 9, and 10 Hz, plus 18, 19, and 20 Hz) (higher-pressure/variable-frequency HFCWC) results in greater sputum expectoration than lower-pressure/mid-frequency HFCWC.
METHODS: This was a controlled randomized crossover study. Sixteen clinically stable, adult CF patients participated. Patients performed airway clearance with HFCWC, once each with lower-pressure/mid-frequency HFCWC and higher-pressure/variable-frequency HFCWC, on separate occasions. All sputum produced during each session was collected. Patients completed pulmonary function tests before and after each session.
RESULTS: Median sputum wet weight was greater with higher-pressure/variable-frequency HFCWC than with lower-pressure/mid-frequency HFCWC (6.4 g, range 0.49-22.0 g, versus 4.8 g, range 0.24-15.0 g, P = .02). Dry sputum weight differences did not reach statistical significance (higher-pressure/variable-frequency HFCWC 0.20 g, range 0.009-0.62 g, lower-pressure/mid-frequency HFCWC 0.12 g, range 0.0001-1.0 g, P = .23). Higher-pressure/variable-frequency HFCWC and lower-pressure/mid-frequency HFCWC resulted in similar increases in FEV(1) (70 mL vs 90 mL, P = .21) and forced vital capacity (80 mL vs 80 mL, P = .94). Post-therapy sputum viscoelastic properties did not differ. Patients perceived the 2 regimens as equally comfortable and effective (P = .35 and P = .35, respectively).
CONCLUSIONS: In adult CF patients, single-session higher-pressure/variable-frequency HFCWC resulted in greater sputum expectoration by wet weight, but not other differences, compared to the commonly used lower-pressure/mid-frequency settings. Longer-term comparisons are needed in a larger, more diverse population to determine whether sustained use of the higher-pressure/variable-frequency settings results in clinically important differences in outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20507651

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

1.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Milroy
Journal:  Cochrane Database Syst Rev       Date:  2020-04-30

Review 2.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Innes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-04

Review 3.  Airway clearance techniques for bronchiectasis.

Authors:  Annemarie L Lee; Angela T Burge; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2015-11-23

4.  Safety and effectiveness of the high-frequency chest wall oscillation vs intrapulmonary percussive ventilation in patients with severe COPD.

Authors:  Antonello Nicolini; Bruna Grecchi; Maura Ferrari-Bravo; Cornelius Barlascini
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-16

5.  The effectiveness of a mobile high-frequency chest wall oscillation (HFCWO) device for airway clearance.

Authors:  Glenn Leemans; Dennis Belmans; Cedric Van Holsbeke; Brian Becker; Dirk Vissers; Kris Ides; Stijn Verhulst; Kim Van Hoorenbeeck
Journal:  Pediatr Pulmonol       Date:  2020-04-22

6.  Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis.

Authors:  Antonello Nicolini; Federica Cardini; Norma Landucci; Sergio Lanata; Maura Ferrari-Bravo; Cornelius Barlascini
Journal:  BMC Pulm Med       Date:  2013-04-04       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.